Investment Insights

Novo Nordisk (NVO) at $50: The Weight-Loss King’s Fall from Glory-Is a $70 Comeback Ahead or Just a Dead-Cat Bounce?

Novo Nordisk: From Glory to Grit — Is This the Comeback Wall Street Isn’t Seeing Coming?”

Once the undisputed king of weight-loss drugs, Novo Nordisk (NVO) now finds itself in unfamiliar territory — trading at just $50, nearly 55% below its 2024 highs. The Danish pharma giant that brought the world Ozempic and Wegovy has seen investor sentiment flip from euphoria to fear.

read more

Vallourec (VK): The Silent Fall of the Steel Giant — Hidden Opportunity or Value Trap?

🚨 Vallourec is falling… or gearing up for a rebound?
📉 Revenues and margins are down, factories closing, oil demand weakening.
💪 With the stock currently trading around €15.60–€15.80, and backed by strong finances + energy‑diversification, there’s a real potential rebound from 2026.
💡 For patient investors: an opportunity to watch!

read more